Development of tri leaflet polymeric heart valves
RUA Structural Heart holds the intellectual property relating to the Company’s synthetic heart valve technology and through an exclusive licence with RUA Biomaterials has exclusive rights to Elast-Eon™ for the formation of heart valve leaflets.
RUA Structural Heart has partnered with RUA Medical to manufacture the synthetic heart valve utilising a novel manufacturing process and valve design, the IP of which will reside in RUA Structural Heart.
RUA Structural Heart has the opportunity to transform the global treatment of heart disease by delivering a synthetic heart valve that will be durable, so reducing the need for future replacement, and should not require lifelong drug treatment. As well as these clinical advantages, the manufacturing costs of a synthetic valve are expected to be considerably less than those of current valve technology making this a potentially disruptive advance in heart valve surgery.